On Jan. 12, Aeropostale, Inc. (NYSE:ARO), a mall-based specialty retailer of casual apparel for young women and men, and DoSomething.org, the largest not-for-profit organization for young people and social change are now accepting jean donations for the eighth annual Teens for Jeans campaign. Aeropostale, Inc. (NYSE:ARO) belongs to Services sector. Its net profit margin is -13.70% and weekly performance is -8.45%. On last trading day company shares ended up $2.71. Aeropostale, Inc. (NYSE:ARO) distance from 50-day simple moving average (SMA50) is 0.63%.
On Jan. 22, The Michaels Companies, Inc. (NASDAQ:MIK) announced the pricing of an underwritten public offering by certain of its stockholders of 18,800,000 shares of its common stock at a price of $23.52 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,820,000 shares of common stock. The selling stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company. The Michaels Companies, Inc. (NASDAQ:MIK) shares advanced 8.76% in last trading session and ended the day at $25.58. MIK Gross Margin is 39.70% and its return on assets is 10.60%. The Michaels Companies, Inc. (NASDAQ:MIK) quarterly performance is 39.55%.
Domtar Corp (NYSE:UFS) has been given a consensus recommendation of “Buy” by the fourteen analysts that are currently covering the stock, AnalystRatingsNetwork reports. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. On 23 January, Domtar Corporation (NYSE:UFS) shares decreased -3.85% and was closed at $38.00. UFS EPS growth in last 5 year was 17.10%. Domtar Corporation (NYSE:UFS) year to date (YTD) performance is -5.52%.
On Jan. 21, Myriad Genetics Inc. (NASDAQ:MYGN) announced that it will issue financial results for the fiscal second quarter 2015 and provide a business update following the close of market on Tuesday, February 3, 2015. Myriad Genetics Inc. (NASDAQ:MYGN) ended the last trading day at $36.20. Company weekly volatility is calculated as 4.02% and price to cash ratio as 16.56. Myriad Genetics Inc. (NASDAQ:MYGN) showed a weekly performance of -8.24%.
On Jan. 12, Fate Therapeutics, Inc. (NASDAQ:FATE) announced key pipeline objectives for 2015. Report Full Data on the Primary Efficacy Endpoint in mid-2015 from the Phase 2 PUMA Study of PROHEMA. Report Topline Data in 2015 from the Phase 1b PROVIDE Study of PROHEMA. Fate Therapeutics is currently initiating the clinical investigation of PROHEMA as a cellular enzyme replacement therapy for pediatric patients with inherited metabolic disorders (IMDs). Fate Therapeutics, Inc. (NASDAQ:FATE) shares advanced 1.04% in last trading session and ended the day at $4.85. FATE return on assets is -51.90%. Fate Therapeutics, Inc. (NASDAQ:FATE) quarterly performance is 2.54%.